Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 40mg+20mg 60tk; 40mg+20mg 100tk; 40mg+20mg 20tk; 40mg+20mg 30tk; 40mg+20mg 56tk; 40mg+20mg 10tk; 40mg+20mg 14tk; 40mg+20mg 50tk

Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 15mg+7,5mg 30tk; 15mg+7,5mg 20tk; 15mg+7,5mg 14tk; 15mg+7,5mg 60tk; 15mg+7,5mg 28tk

Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 10mg+5mg 14tk; 10mg+5mg 56tk; 10mg+5mg 28tk; 10mg+5mg 30tk; 10mg+5mg 98tk; 10mg+5mg 60tk; 10mg+5mg 100tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 5mg+2,5mg 10tk; 5mg+2,5mg 7tk; 5mg+2,5mg 14tk; 5mg+2,5mg 98tk; 5mg+2,5mg 100tk; 5mg+2,5mg 28tk; 5mg+2,5mg 56tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 10mg+5mg 10tk; 10mg+5mg 50tk; 10mg+5mg 14tk; 10mg+5mg 30tk; 10mg+5mg 60tk

Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 80mg+40mg 28tk; 80mg+40mg 14tk; 80mg+40mg 60tk; 80mg+40mg 30tk; 80mg+40mg 56tk; 80mg+40mg 98tk

Eesti - eesti - Ravimiamet

g.l. pharma gmbh - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 40mg+20mg 30tk; 40mg+20mg 7tk; 40mg+20mg 20tk; 40mg+20mg 14tk; 40mg+20mg 100tk; 40mg+20mg 28tk; 40mg+20mg 10tk

Eesti - eesti - Ravimiamet

mundipharma ges.m.b.h. - oksükodoon+naloksoon - toimeainet prolongeeritult vabastav tablett - 60mg+30mg 28tk; 60mg+30mg 56tk; 60mg+30mg 14tk; 60mg+30mg 100tk; 60mg+30mg 60tk; 60mg+30mg 30tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastilised ained - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Euroopa Liit - eesti - EMA (European Medicines Agency)

axunio pharma gmbh - pirfenidone - idiopaatiline kopsufibroos - immunosupressandid - pirfenidone aet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).